US4312872A
Expired / Lapsed
US
⏱️ 0.0 years remaining
1-Alka-2,4-dienyl-2-hydroxymethyl-3,4,5-trihydroxypiperidines as inhibitors of α-glucoside hydrolases
Assignee: Bayer AG
•
Filing: 1980-06-11
•
Granted: 1982-01-26
•
Expires: 2000-06-11
Abstract
Abstract The invention relates to 1-alka-2,4-dienyl-2-hydroxymethyl-3,4,5-trihydroxypiperidine compounds which are, inter alia, potent inhibitors for α- glucoside hydrolases and effect lipid absorption. Also included in the invention are methods for the manufacture of the said compounds, compositions containing said compounds and methods for the use of said compounds and compositions.
Inventors
- 👤 Bodo Junge
- 👤 Lutz Muller
- 👤 Rudiger Sitt
- 👤 Gunter Thomas
- 👤 Hans P. Krause
- 👤 Walter Puls
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 18:06
CPC Classifications
C; C07; C07D; C07D211/00; C07D211/04; C07D211/06; C07D211/36; C07D211/40; C07D211/44; C07D211/46; A; A61; A61P; A61P3/00; A61P3/06; A61P3/08; A61P3/10; A61P43/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
27 words
A 2-hydroxymethyl-3,4,5-trihydroxypiperidine derivative of the formula ##STR9## in the form of individual stereoisomers or mixtures thereof, in which n is 0, 1, 2, 3, 4 or 5.
Claim 2
Dependent Claim
27 words
A 2-hydroxymethyl-3,4,5-trihydroxypiperidine derivative of the formula ##STR9## in the form of individual stereoisomers or mixtures thereof, in which n is 0, 1, 2, 3, 4 or 5.
Claim 3
Dependent Claim
16 words
A compound according to claim 1 in which n is 1, 2, 3, 4 or 5.
Claim 4
Dependent Claim
9 words
A compound according to claim 1 which is N-hexa-2,4-dienyl-1-desoxynijirimicin.
Claim 5
Dependent Claim
9 words
A compound according to claim 1 which is N-penta-2,4-dienyl-1-desoxynojirimicin.
Claim 6
Dependent Claim
35 words
A pharmaceutical composition containing as an active ingredient an amount effective for treating adiposity, diabetes or lipoproteinaemia, of a compound according to claim 1 in admixture with a solid, liquid or liquefied gaseous pharmaceutical diluent.
Claim 7
Dependent Claim
18 words
A composition according to claim 5 containing from 0.1 to 99.5% by weight of the said active ingredient.
Claim 8
Dependent Claim
29 words
A medicament in dosage unit form comprising an amount effective for treating adiposity, diabetes or lipoproteinaemia, of a compound according to claim 1 together with an inert pharmaceutical carrier.
Claim 9
Dependent Claim
16 words
A medicament of claim 7 in the form of tablets, pills, dragees, capsules, ampoules, or suppositories.
Claim 10
Dependent Claim
50 words
A method of combating adiposity, diabetes or lipoproteinaemia in warm-blooded animals which comprises administering to the animals an amount effective for treating adiposity, diabetes or lipoproteinaemia, of an active compound according to claim 1 either alone or in admixture with a pharmaceutical diluent or in the form of a medicament.
Claim 11
Dependent Claim
27 words
A method according to claim 9 in which the active compound is administered in an amount of 0.5 to 100 mg per kg body weight per day.
References Cited (Backward Citations)
US4182767A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-01-25 | 1985-07-27 | 1986-01-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-01-25 | 1989-07-27 | 1990-01-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-01-25 | 1993-07-27 | 1994-01-26 | $7700.00 | Window Closed / Lapsed |